Abstract-The 21-amino acid peptide endothelin-1 (ET-1) is the predominant isoform of the endothelin peptide family, which includes ET-2, ET-3, and ET-4. It exerts various biological effects, including vasoconstriction and the stimulation of cell proliferation in tissues both within and outside of the cardiovascular system. ET-1 is synthesized by endothelin-converting enzymes (ECE), chymases, and non-ECE metalloproteases; it is regulated in an autocrine fashion in vascular and nonvascular cells. ET-1 acts through the activation of G i -protein-coupled receptors. ET A receptors mediate vasoconstriction and cell proliferation, whereas ET B receptors are important for the clearance of ET-1, endothelial cell survival, the release of nitric oxide and prostacyclin, and the inhibition of ECE-1. ET is activated in hypertension, atherosclerosis, restenosis, heart failure, idiopathic cardiomyopathy, and renal failure. Tissue concentrations more reliably reflect the activation of the ET system because increased vascular ET-1 levels occur in the absence of changes in plasma. Experimental studies using molecular and pharmacological inhibition of the ET system and the first clinical trials have demonstrated that ET-1 takes part in normal cardiovascular homeostasis. Thus, ET-1 plays a major role in the functional and structural changes observed in arterial and pulmonary hypertension, glomerulosclerosis, atherosclerosis, and heart failure, mainly through pressure-independent mechanisms. ET antagonists are promising new agents in the treatment of cardiovascular diseases. (Circulation. 2000;102:2434-2440.) Key Words: atherosclerosis Ⅲ restenosis Ⅲ heart failure Ⅲ hypertension Ⅲ transplantation Ⅲ nitric oxide
Biosynthesis and Regulation
In the endothelium, ET-1 is predominantly released abluminally toward the vascular smooth muscle, suggesting a paracrine role. 21 ET-1 is also produced by other cells involved in vascular disease, such as leukocytes, 22 macrophages, 23 smooth muscle cells, 24 cardiomyocytes, 25, 26 and mesangial cells, 27, 28 and its synthesis is regulated in an autocrine fashion. 24 -26,29 -33 Transcriptional Regulation Transcription of the preproendothelin gene is regulated through the phorbol-ester-sensitive c-fos and c-jun complexes, 34 acute phase reactant regulatory elements, 35 and binding sites for nuclear factor-1, 36 AP-1, and GATA-2. 37, 38 The translation of preproendothelin mRNA results in the formation of a 203-amino acid preproendothelin peptide, which is cleaved by a furin convertase 39 to the 38-amino acid peptide big ET-1 40 (Figures 1 and 2 ).
Endothelin-Forming Enzymes
Once formed, big ET-1 is processed to ET-1 1-21 through cleavage of the Trp 21 -Val 22 bond by ET-converting enzyme-1 (ECE-1), which exists in 4 isoforms (a, b, c, and d) , [41] [42] [43] [44] [45] [46] and by ECE-2 47 and chymase. 48 In addition, chymase cleaves big ET-1 at the Tyr 31 -Gly 32 bond, resulting in the formation of ET-1 1-31
49
( Figure 1 ). ECE-3 selectively converts big ET-1 into ECEs are localized in endothelial 41, 45 and smooth muscle cells, [51] [52] [53] cardiomyocytes, 54,55 and macrophages. 52,55 ECE-like activity has been demonstrated in the human serum lipoprotein fraction. 56 ECEs belong to the metalloprotease family, 41, 44, 47 share functional and structural similarity with neutral endopeptidases and Kell blood group proteins, 57, 58 and are partially inhibited by phosphoramidon. 59 These enzymes are not selective for big ET-1; they also hydrolyze peptides such as bradykinin, substance P, and insulin. 60,61 ECE-1 expression is regulated through protein kinase C-dependent mechanisms, 62 ET Breceptors, 63 the transcription factor ets-1, 64 and cytokines. 65 In ECE-1 knockout mice, tissue levels of ET-1 are reduced by only one-third. 66 Thus, ECE-independent pathways also contribute to ET-1 production. Indeed, chymase generates ET-1 . 48 In addition, 2 novel ET-1 1-21 -forming enzymes, a non-ECE metalloprotease and a vascular smooth muscle cell chymase, have been cloned (Figure 1 ). 
Factors Regulating Synthesis

Cardiovascular Actions
In addition to its vasoconstrictive 5 and mitogenic effects, 30, 88 ET stimulates the production of cytokines 89, 90 and growth factors such as vascular endothelial growth factor, 82 basic fibroblast growth factor-2, 91 and epiregulin. 92 ET-1 also induces the formation of extracellular matrix proteins 93 and fibronectin, 94 and it potentiates the effects of transforming growth factor-␤ 95 and platelet-derived growth factor 96 ( Figure  3 ). Of note, ET-1 interacts with the blood cells stimulating neutrophil adhesion 97 and platelet aggregation, 98 and it is a chemotactic factor for macrophages. 99 Finally, ET-1 promotes cell-cycle progression in an autocrine fashion. 100 -102 ET-1, predominantly via ET A receptors, promotes vasoconstriction, cell growth, cell adhesion, and thrombosis; thus, ET-1 is a promising target for cardiovascular therapy. 108 and an ET C receptor selective for ET-3 has been found in frogs. 109 In the vasculature, ET A receptors are found in smooth muscle cells, whereas ET B receptors are localized on endothelial cells and, to some extent, in smooth muscle cells 110 and macrophages. 111 The affinity of ET A receptors for ET-1 and ET-2 is Ͼ100-fold higher than for ET-3, whereas ET B receptors bind ET isopeptides with a 
Receptor Classification and Function
Value of Plasma Levels
In the clinical setting, only plasma concentrations of ET-1 can be measured; these concentrations are affected by the production, clearance, and breakdown of 126 ET-1 plasma levels are high in children 127 but rather low (1 to 2 pg/mL) in adults, and the levels are different between races. 128 In atherosclerosis, 52,129,130 myocardial infarction, 131 pulmonary hypertension, 132 heart failure, 133 and renal failure, 134 ET-1 levels are elevated in both tissue and plasma. The expression of ET-1 protein is enhanced by ischemia 135, 136 and/or mechanical injury (ie, balloon angioplasty). 137, 138 Therefore, in many cardiovascular diseases, increased plasma ET-1 levels are a marker of ET activation. Depending on the condition, such changes may reflect increased production, reduced clearance, and/or the metabolism of ET-1. In patients treated with nonselective ET antagonists, ET-1 plasma levels increase 139,140 because of reduced ET Bmediated pulmonary clearance. 123
Which Receptor Should Be Blocked?
Given the opposing actions of the ET A and ET B receptors, therapeutic applications must be carefully assessed. ET antagonists can block either ET A or ET B receptors or both. 141 The blockade of ET B receptors impairs the pulmonary clearance of ET-1 123 and reduces NO-mediated vasodilatation. 142 Interestingly, an infusion of ET B antagonists increases systemic vascular resistance in humans, 143 and ET B receptor deficiency is associated with hypertension in mice. 144 Thus, during chronic hypoxia, the increase in ET B receptor expression and ET B -mediated, NO-mediated vasodilation 145 may provide additional vasodilatory capacity. However, in most experimental 146 -148 and clinical studies, 139, 140, 149 combined antagonists improved cardiovascular function and structure, suggesting that therapeutic effects can be expected provided that ET A receptors are blocked, regardless of concomitant ET B receptor blockade.
Current Compounds
Several peptides and nonpeptide compounds that block ET receptors are now available, and some are in clinical development (Table) . The inhibition of ECE inhibits the production of ET-1. However, the recent identification of ECE-independent pathways contributing to ET-1 formation, such as chymase and non-ECE metalloprotease, limits the effectiveness of these drugs. In addition to the blockade of ET receptors, ET-1 production can be inhibited indirectly through renin-angiotensin system inhibitors 150,151 or statins, which reduce ET-1 expression independently of their lipid-lowering effects. 152 In the future, antisense gene therapy 153,154 may be useful, as has been for other G i -protein-coupled receptors. 155
Safety
Because of their teratogenic effects, which lead to craniofacial and organic malformations, 12 ET antagonists are contraindicated during pregnancy and in women with child-bearing potential. In clinical trials, the administration of ET antagonists was occasionally associated with an increase in heart rate, facial flush, and/or facial edema, 156 probably because of cerebral vasodilatation. A nitrate-like headache occurred in healthy volunteers but was less strong in patients. 157 Potential gastrointestinal side effects include nausea, vomiting, and constipation. Also, certain ET antagonists may interfere with anticoagulants (ie, warfarin). 158 Additional hypotensive effects may occur if ET antagonists are combined with angio- Figure 3 . Vascular effects of ET-1. ET-1 is generated in endothelial and smooth muscle cells in response to oxidized LDL, angiotensin II (Ang II), etc. The stimulation of endothelial ET B receptors increases the release of NO, whereas ET A receptors mediate contraction and cell proliferation and migration. ET-1 stimulates interleukin (IL) and tumor necrosis factor-␣ (TNF␣) expression in monocytes, leukocyte adherence, platelet aggregation, and adhesion molecule expression. ET-1 stimulates the production and action of growth factors, DNA and protein synthesis, and cell cycle progression. ONOOϪ indicates peroxynitrite; NOS, nitric oxide synthase; MCP-1, monocyte chemoattractant protein-1; ICAM-1, intracellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; oxLDL, oxidized low density lipoprotein; O 2 Ϫ, superoxide anion; LOX, lectin-like oxidized LDL receptor; TGF ␤-1, transforming growth factor-␤1; NADPHox, nicotinamide adenine dinucleotide phosphate oxidase; PAI-1, plasminogen activator inhibitor-1; VEGF, vascular endothelial growth factor; bFGF-2, basic fibroblast growth factor-2; PDGF, platelet-derived growth factor; ϩ, stimulation; and Ϫ, inhibition. tensin-converting enzyme (ACE) inhibitors. 159 -161 Long-term studies using high doses of bosentan in patients with chronic heart failure were associated with the marked elevation of liver enzymes.
Endothelin Antagonists
Therapeutic Targets Hypertension and Renal Disease
Patients with ET-1-producing hemangioendotheliomas are hypertensive, and their blood pressure normalizes after surgery. 162 ET-1 levels, however, are low in most hypertensives, except those who are black. 163 In patients with essential hypertension, bosentan showed an antihypertensive efficacy similar to the ACE inhibitor enalapril. 157 In angiotensin II-induced, salt-sensitive hypertension in deoxycorticosterone acetate-salt rats and Dahl rats, chronic ET receptor blockade lowers blood pressure, whereas in spontaneously hypertensive rats, this blockade is ineffective. Similarly, the pharmacological or molecular inhibition of ET-1 demonstrated that ET contributes to vascular hypertrophy and that local expression of ET-1 increases in vascular and renal tissue in most, 31,164 -166 but not all, forms of experimental hypertension. 167, 168 Thus, an increase in blood pressure per se is not sufficient to activate the ET system, 169 a concept supported by the finding that rats transgenic for the human ET-1 gene exhibit profound vascular hypertrophy and glomerulosclerosis but lack hypertension. 170 Studies in L-N G -nitroarginine methyl ester hypertension suggest that ET-1 is linked to the dysfunction of the L-arginine/NO pathway 171 because ET A -selective 172 but not combined ET blockade 173 improves endothelial function, independent of blood pressure. Thus, selective inhibition of ET A receptors improves the endothelial L-arginine/NO pathway, which agrees with observations in humans. 142 This is supported by the fact that the concomitant blockade of ET B receptors abolishes the beneficial effects of an ET A -selective antagonist on vascular structure. 174 ET-1 promotes vasoconstriction and cell growth in the vasculature and in the kidney. Accordingly, in experimental models, chronic ET receptor blockade inhibits vascular injury (Figure 4) , reduces hypertension-associated 31, 165, 166, [175] [176] [177] [178] [179] and other forms of renal and vascular injury, 134,180 -182 and also prolongs survival. 183, 184 Occlusive Vascular Disease Atherosclerosis Hypercholesterolemia leads to endothelial dysfunction 185 and is associated with increased ET levels in plasma 186 and tissue. 187 Oxidized LDL induces ET-1 gene expression in endothelial cells 72 and the proliferation of vascular smooth muscle cells via ET A receptors. 188 In addition, the increased release of ET-1 stimulates the synthesis of transforming growth factor-␤1, basic fibroblast growth factor, epiregulin, platelet-derived growth factor, and various adhesion molecules implicated in atherogenesis (Figure 3) . ET-1 also increases neutrophil 97 and platelet adhesion, thereby promoting lesion growth and coronary thrombosis. In experimental hypercholesterolemia, ET A receptor blockade reduced macrophage infiltration in fatty streaks. 189 In hypercholesterolemic pigs, impaired endothelium-dependent vasodilatation is improved after ET receptor blockade. 190 In apolipoprotein E-deficient mice, ET-1 is involved in atherogenesis. 191 Long-term ET A blockade reduces the extent of atherosclerosis, without affecting blood pressure or plasma cholesterol; it also restores NO-mediated endotheliumdependent relaxation and prevents increased vascular ET-1 ( Figure 5 ). 191 ET-1 also contributes to myocardial infarction in mice with atherosclerosis. 192 ET receptor blockade is also effective in reducing ischemic brain injury and vaso- spasm, 184, 193 2 major factors determining the severity of stroke and its sequelae.
Coronary Artery Disease
In atherosclerotic human arteries, ET A receptor mRNA is downregulated, 194 while the binding capacity of ET A receptors is increased in atherosclerotic mice. 191 In patients with angina pectoris but normal angiograms 195 and in those with coronary artery disease 129 and acute myocardial infarction, 131 ET-1 plasma levels are increased. In human atherosclerotic lesions, the expression of ET-1 and ECE is enhanced. 52, 53, 129, 196 A functional role for tissue ET-1 in coronary artery disease is suggested by the observation that the extent of immunoreactive staining for ET-1 in atheromatous lesions is related to angina class. 130 In line with this observation, ET A /ET B receptor blockade causes vasodilation, at least in certain patients with coronary atherosclerosis. 149
Restenosis
Restenosis is a major limitation of balloon angioplasty. Experimentally, the ET system is activated after vascular injury for several weeks. 137 The extent of restenosis can be augmented by concomitant infusion of Consequently, ET receptor blockade is effective in reducing neointima formation after balloon angioplasty in both rodents and pigs. 198 -201 Transplant-Associated Arteriosclerosis Organ transplantation is associated with an increase in circulating ET-1 levels, probably because of the activation of the ET system in the transplanted kidney, 202 heart, 203 coronary circulation, 204 and the lung. 205, 206 In rats, transplantassociated obliterative bronchiolitis 207 can be mimicked by pulmonary preproendothelin-1 gene transfer in vivo. 208 ET receptor blockade reduces reperfusion injury and improves graft survival after lung transplantation. 209 It also inhibits transplant arteriosclerosis after heterotopic heart transplantation in rats concomitantly treated with cyclosporin A. In line with findings in the heart, ET A receptor blockade inhibits transplant-associated glomerulosclerosis and arteriosclerosis in the kidney, despite the discontinuation of immunosuppression after 10 days. 210 Interestingly, gene therapy using antisense-oligonucleotides for cdk-2 kinase reduces ET-1 expression in allograft arteries. 211
Pulmonary Hypertension
ET-1 expression in pulmonary tissue is increased in patients with primary and secondary pulmonary hypertension. 132 Circulating ET-1 increases at high altitudes in mountaineers and correlates with pulmonary pressures and oxygen tension. 212 ET increases even more in mountaineers prone to highaltitude pulmonary edema. 213 Similar observations were made in patients with congestive heart failure. 214 In heart failure, elevated ET-1 plasma levels 215 are, at least in part, related to impaired ET B receptor-mediated clearance. 216 Acute and short-term treatment of heart failure patients with the nonselective ET antagonist bosentan markedly lowers pulmonary artery pressure. 139, 140 However, the increase in circulating ET-1 during therapy suggests that ET B -mediated clearance 123 is reduced by bosentan. In experimental studies of hypoxia-induced 217,218 and monocrotaline-induced pulmonary hypertension, 219 chronic ET receptor blockade lowered pulmonary artery pressures and the incidence of vascular and pulmonary injury and improved NO-mediated pulmonary vasodilatation. Similar observations were made in rats with high altitude-sensitive pulmonary hypertension. 220
Congestive Heart Failure and Left Ventricular Dysfunction
Heart failure due to coronary artery disease or hypertension is a major cause of morbidity and mortality. 221 Although ACEinhibitors, ␤-blockers, and spironolactone reduce cardiovascular events, prognosis remains poor. In experimental animals and in patients with heart failure, the plasma levels of ET-1 are increased, 222-226 and they predict survival. 226 The growth-promoting effects of ET-1 on cardiomyocytes 25, 26, 227, 228 have been implicated in the development of left ventricular hypertrophy. Cardiac growth can be augmented by hypoxia, 229 which may be important in chronic ischemia. In addition, ET-1-mediated cardiac hypertrophy is enhanced by the renin-angiotensin system. 26,230 However, the mechanism by which ET-1 affects the progression of left ventricular hypertrophy into heart failure seems to be biphasic. Prolonged exercise in rats leads to the upregulation of myocardial ET expression. 70 Similarly, in early stages of heart failure, ET-1 maintains cardiac function as ET A receptor inhibition worsens contractility. 231 ET A receptors, ECE, and the preproendothelin gene are upregulated in heart failure in rats and humans 55, [231] [232] [233] [234] and in hamsters with dilated cardiomyopathy, 228 and they contribute to impaired ventricular function. 235 In animal models of chronic heart failure, prolonged ET blockade improves cardiac hemodynamics, reduces ventricular dilatation, and prolongs survival (Figure 6 ). 233,236 -239 The time point for the initiation of treatment, however, may be important because ET blockade can interfere with scar formation in injured myocardium. 240 Whether selective ET A or nonselective ET blockade should be favored in heart failure is unclear. Beneficial hemodynamic and clinical effects occur with ET A receptor blockade, both with selective and nonselective ET antagonists. However, concomitant ET B blockade markedly increases circulating ET-1 levels. Whether this is of clinical relevance is unknown. Endothelin antagonists increase blood flow in the forearm conduit arteries 241 and skin microcirculation, 242 an effect that seems to involve the release of NO mediated by the blockade of ET A receptors. 142 Although increased ET B -mediated systemic vasoconstriction has been reported in patients with heart failure, 243 ET B receptor blockade may abrogate the beneficial effects of ET A receptor blockade on cardiac hemodynamics and renal function in humans and animals with heart failure. 244, 245 The first hemodynamic studies of ET A blockade in humans have been promising. In patients with severe congestive heart failure, acute infusion of the nonselective antagonist bosentan increased cardiac output and reduced systemic and pulmonary resistance. 139, 140 Similar data have been obtained with the selective ET A receptor antagonists BQ-123 and LU135252 (Lüscher and Barton, unpublished data, 1999) . The beneficial clinical and hemodynamic effects of the blockade persist, and the increase in cardiac index is even more pronounced after 2 weeks of chronic treatment with bosentan 140 (Figure 7) . The Research on Endothelin Antagonism in Chronic Heart failure (REACH-1) trial with bosentan was terminated early because of hepatic side effects. The results showed an early worsening (at 3 months) and a potential benefit at 6 months, with decreased symptoms and reduced progression of heart failure. Possibly, the high dosages used without up-titration in the first weeks of therapy worsened heart failure in some patients. Lower dosages of bosentan are now being evaluated in the Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure (ENABLE) trial. Whether selective ET A blockade will improve clinical symptoms and outcome in heart failure is currently being investigated in several small trials.
Conclusions
The ET system is involved in cardiovascular control and disease progression. ET receptor blockade has been shown to have therapeutic potential in experimental and early clinical studies of hypertension, atherosclerosis, heart failure, pulmonary disease, and renal end-organ damage. Controlled clinical studies will determine whether these new drugs, which promise to be powerful tools in cardiovascular medicine, have the potential to reduce morbidity and mortality. Effects of ET A /ET B antagonist bosentan on hemodynamics in patients with congestive heart failure. On day 1, bosentan decreased mean arterial pressure, mean pulmonary artery and capillary wedge pressures, and right atrial pressure. Cardiac output increased, with no change in heart rate. Both systemic and pulmonary vascular resistance were reduced. After 2 weeks, cardiac output further increased, and systemic and pulmonary vascular resistances decreased compared with day 1. BP indicates blood pressure; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; CI, cardiac index; SVI, stroke volume index; SVR, systemic vascular resistance; and PVR, pulmonary vascular resistance. Reproduced with permission from Sü tsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998; 98:2262 -2268 
